This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
ARDS, Human
+2

Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

Last updated 3 years ago

Study ID

PEGASUS

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18 to 100 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 3 years ago

What is this trial about?

Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.

What are the participation requirements?

Yes

Inclusion Criteria

- Admitted to a participating ICU,

- invasively ventilated and

- fulfil the Berlin criteria for moderate or severe ARDS.

No

Exclusion Criteria

- Age under 18,

- participation in other interventional studies with conflicting endpoints,

- conditions in which LUS is not feasible or possible (e.g. subcutaneous emphysema, morbid obesity or wounds),

- mechanical ventilation for longer than 7 consecutive days in the past 30 days,

- history of ARDS in the previous month,

- body-mass index higher than 40 kg/m²,

- intracranial hypertension,

- broncho-pleural fistula,

- chronic respiratory diseases requiring long-term oxygen therapy or respiratory support,

- pulmonary fibrosis with a vital capacity < 50% (severe or very severe),

- previously randomized in the PEGASUS study

- ECMO

- patients who are moribund or facing end of life and

- no informed consent.

Locations

Location

Status

Recruiting